| Factor Information | |
|---|---|
| Data ID | 1899 |
| Factor | correlation between intestinal FABP 2 and symptoms of feeding intolerance |
| Description | Variation in biomarker concentrations over time was associated with aspects of ICU care indicating greater severity of illness: claudin 3, intestinal fatty acid–binding protein 2, and dual sugar permeability test ratio were associated with symptoms of feeding intolerance (p< 0.05). Claudin 3 (p = 0.02) concentrations and FABP2 (p = 0.02) were significantly associated with symptoms of feeding intolerance, mixed effects linear regression. Several clinical factors indicating greater severity of illness remote from CPB were also associated with symptoms of feeding intolerance (p = 0.01) . |
| Biomarker | NA |
| Classification | Z (combined factor - combined factor) |
| Association | |
|---|---|
| Application | prognosis and risk assessment |
| Objective | greater severity of illness, symptoms of feeding intolerance, mixed effects linear regression |
| p Value | <0.05 |
| Conclusion | Variation in biomarker concentrations over time was associated with aspects of ICU care indicating greater severity of illness: claudin 3, intestinal fatty acid–binding protein 2, and dual sugar permeability test ratio were associated with symptoms of feeding intolerance (p< 0.05). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 563 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | TOF/SD/AVC/AS/SS/CoA, HAA/MV/TAPVR/PS/PA/PI/DORV/EA |
| Reference | |
|---|---|
| PMID | 25162512 |
| Year | 2015 |
| Title | Clinical characteristics associated with postoperative intestinal epithelial barrier dysfunction in children with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | blood, urine | |
| Region | Tucson, USA | |
| Method | ELISA, triple-quadrupole mass spectrometer, Cytokine concentrations were evaluated using an xMAP assay and Luminex 100 platform, HPLC | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | repair or palliation of congenital heart disease with cardiopulmonary bypass. | |
| Group | N/A(Treatment) | N/A(Control) |
| Number | 20 | N/A |
| Age | 17 (3.1–76.9) months | N/A |
| Gender (Male: Female) | 14:20 | N/A |
| Marker Level | N/A | N/A |
